Programming of cardiometabolic health: the role of maternal and fetal hyperinsulinaemia.
View / Open Files
Publication Date
2022-04-05Journal Title
J Endocrinol
ISSN
0022-0795
Publisher
Bioscientifica
Volume
253
Issue
2
Pages
R47-R63
Type
Article
This Version
VoR
Physical Medium
Electronic
Metadata
Show full item recordCitation
Hufnagel, A., Dearden, L., Fernandez-Twinn, D. S., & Ozanne, S. E. (2022). Programming of cardiometabolic health: the role of maternal and fetal hyperinsulinaemia.. J Endocrinol, 253 (2), R47-R63. https://doi.org/10.1530/JOE-21-0332
Abstract
Obesity and gestational diabetes during pregnancy have multiple short- and long-term consequences for both mother and child. One common feature of pregnancies complicated by maternal obesity and gestational diabetes is maternal hyperinsulinaemia, which has effects on the mother and her adaptation to pregnancy. Even though insulin does not cross the placenta insulin can act on the placenta as well affecting placental growth, angiogenesis and lipid metabolism. Obese and gestational diabetic pregnancies are often characterised by maternal hyperglycaemia resulting in exposure of the fetus to high levels of glucose, which freely crosses the placenta. This leads to stimulation of fetal ß-cells and insulin secretion in the fetus. Fetal hyperglycaemia/hyperinsulinaemia has been shown to cause multiple complications in fetal development, such as altered growth trajectories, impaired neuronal and cardiac development and early exhaustion of the pancreas. These changes could increase the susceptibility of the offspring to develop cardiometabolic diseases later in life. In this review, we aim to summarize and review the mechanisms by which maternal and fetal hyperinsulinaemia impact on (i) maternal health during pregnancy; (ii) placental and fetal development; (iii) offspring energy homeostasis and long-term cardiometabolic health; (iv) how interventions can alleviate these effects.
Keywords
developmental programming, fetal hyperinsulinaemia, gestational diabetes, maternal hyperinsulinaemia, pregnancy, Cardiovascular Diseases, Female, Fetal Development, Fetus, Humans, Hyperinsulinism, Placenta, Pregnancy
Sponsorship
Medical Research Council (MC_UU_12012/4)
British Heart Foundation (RG/17/12/33167)
Wellcome Trust (106026/Z/14/Z)
Wellcome Trust (108926/B/15/Z)
British Heart Foundation (PG/20/11/34957)
MRC (MC_UU_00014/5)
Identifiers
External DOI: https://doi.org/10.1530/JOE-21-0332
This record's URL: https://www.repository.cam.ac.uk/handle/1810/337580
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: support@repository.cam.ac.uk